ALAN LOPEZ: Open Payments
NPI 1689429326 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 23 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,057 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $136 |
| ABBVIE INC. | 3 | $73 |
| E.R. Squibb & Sons, L.L.C. | 3 | $67 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Alkermes, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Novo Nordisk Inc | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
Products named: INGREZZA, VRAYLAR, REXULTI, COBENFY, Auvelity, CAPLYTA, ARISTADA, UZEDY.
Industry payments across NV — which companies pay providers there.
